Skip to main content

Helena Xicoy Cortada

Institutions of which they are part

Postdoctoral researcher
Neurodegenerative Diseases
Vall Hebron Institut de Recerca

Helena Xicoy Cortada

Institutions of which they are part

Postdoctoral researcher
Neurodegenerative Diseases
Vall Hebron Institut de Recerca

Projects

Malalties neurodegeneratives

IP: Miquel Vila Bover
Collaborators: Jorge Hernández Vara, Joan Compte Barrón, Marta Martínez Vicente, Jordi Bove Badell, Eddie Pradas Gracia, Maria Camprodon Gomez, Camille Guillard Sirieix, Marina Lorente Picón, Laura Castillo Ribelles, Oriol de Fabregues-Boixar Nebot, Javier Hoyo Pérez, Ariadna Laguna Tuset, Thais Cuadros Arasa, Jordi Riera Heredia, David Ramos Vicente, Marta Montpeyó Garcia-Moreno, Helena Xicoy Cortada, Alba Nicolau Vera, Marta González Sepúlveda, Joana Margalida Cladera Sastre, Annabelle Parent, Daniela Samaniego Toro, Daniela Samaniego Toro
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 40000
Reference: 2021 SGR 00784
Duration: 01/01/2022 - 30/06/2025

The brain-body axis in Parkinson’s disease patients: from pathophysiology to biomarkers and therapeutic approaches

IP: Ariadna Laguna Tuset
Collaborators: Maria Victoria Gonzalez Martinez, Miquel Vila Bover, Marina Lorente Picón, Helena Xicoy Cortada, Daniela Samaniego Toro, Daniela Samaniego Toro, Sara Belmonte Calderon
Funding agency: Instituto de Salud Carlos III
Funding: 171820
Reference: PI21/01603
Duration: 01/01/2022 - 31/12/2024

Mecanismos moleculares de neurodegeneración ligada a la neuromelanina en la enfermedad de Parkinson y envejecimiento cerebral

IP: Miquel Vila Bover
Collaborators: Thais Cuadros Arasa, Helena Xicoy Cortada, Marta González Sepúlveda, Annabelle Parent
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 332750
Reference: PID2020-116339RB-I00
Duration: 01/09/2021 - 31/08/2024

Ministerio de Ciencia

The Gut-Brain axis in Parkinson's disease: novel pathogenic mechanisms and new possibilities for biomarkers and therapeutic approaches

IP: Ariadna Laguna Tuset
Collaborators: Marina Lorente Picón, Helena Xicoy Cortada
Funding agency: Fundació "La Caixa"
Funding: 303300
Reference: 2018_INCOMING_CAIXA/LAGUNA
Duration: 02/10/2019 - 30/04/2023

Related news

Vall d'Hebron has participated in a phase III clinical trial which confirmed the efficacy and safety of subcutaneous infusion of levodopa therapy.

This initiative is part of a pioneering study that seeks to assess how the relationship between different age groups can influence the quality of life and mental health of patients.

Dr. Miquel Vila, head of the Neurodegenerative Diseases research group at VHIR, is the co-chair of the local organising committee. And Dr. Ariadna Laguna, principal investigator of the same group, is a scientific ambassador.

Related professionals

Lis Vidal Valdivia

Lis Vidal Valdivia

Donation and transplantation of organs, tissues and cells
Read more
Tetiana Gonchorova Simón

Tetiana Gonchorova Simón

Read more
Erica Espejo Basilio

Erica Espejo Basilio

Medium Grade Technician
IT / Information Systems
Digital Transformation Directorate
Read more
Elga Schreiber Bru

Elga Schreiber Bru

Tècnic/a Grau Superior
International Unit
Competitive Research Directorate
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.